Filgrastim-aafi is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology. NIVESTYM is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. NIVESTYM has a molecular weight of 18‚799 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because NIVESTYM is produced in E coli‚ the product is non-glycosylated and thus differs from G-CSF isolated from a human cell.
NIVESTYM is a sterile‚ clear‚ colorless‚ preservative-free liquid containing filgrastim-aafi injection for subcutaneous or intravenous use. The product is available in single-dose vials for subcutaneous or intravenous use and prefilled syringes for subcutaneous use. The single-dose vials contain either 300 mcg/mL or 480 mcg/1.6 mL of filgrastim-aafi. The single-dose prefilled syringes contain either 300 mcg/0.5 mL or 480 mcg/0.8 mL of filgrastim-aafi. The final pH range of the NIVESTYM drug product solution is 3.8 to 4.3. See Table 4 below for product composition of each single-dose vial or prefilled syringe.
| 300 mcg/mL Vial | 480 mcg/1.6 mL Vial | 300 mcg/0.5 mL Syringe | 480 mcg/0.8 mL Syringe | |
|---|---|---|---|---|
| ||||
Filgrastim-aafi | 300 mcg | 480 mcg | 300 mcg | 480 mcg |
Acetate | 0.59 mg | 0.94 mg | 0.295 mg | 0.472 mg |
Polysorbate 80 | 0.04 mg | 0.064 mg | 0.02 mg | 0.032 mg |
Sodium | 0.035 mg | 0.056 mg | 0.0175 mg | 0.028 mg |
Sorbitol | 50 mg | 80 mg | 25 mg | 40 mg |
Water for Injection USP | 1 mL | 1.6 mL | 0.5 mL | 0.8 mL |
Filgrastim-aafi is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology. NIVESTYM is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. NIVESTYM has a molecular weight of 18‚799 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because NIVESTYM is produced in E coli‚ the product is non-glycosylated and thus differs from G-CSF isolated from a human cell.
NIVESTYM is a sterile‚ clear‚ colorless‚ preservative-free liquid containing filgrastim-aafi injection for subcutaneous or intravenous use. The product is available in single-dose vials for subcutaneous or intravenous use and prefilled syringes for subcutaneous use. The single-dose vials contain either 300 mcg/mL or 480 mcg/1.6 mL of filgrastim-aafi. The single-dose prefilled syringes contain either 300 mcg/0.5 mL or 480 mcg/0.8 mL of filgrastim-aafi. The final pH range of the NIVESTYM drug product solution is 3.8 to 4.3. See Table 4 below for product composition of each single-dose vial or prefilled syringe.
| 300 mcg/mL Vial | 480 mcg/1.6 mL Vial | 300 mcg/0.5 mL Syringe | 480 mcg/0.8 mL Syringe | |
|---|---|---|---|---|
| ||||
Filgrastim-aafi | 300 mcg | 480 mcg | 300 mcg | 480 mcg |
Acetate | 0.59 mg | 0.94 mg | 0.295 mg | 0.472 mg |
Polysorbate 80 | 0.04 mg | 0.064 mg | 0.02 mg | 0.032 mg |
Sodium | 0.035 mg | 0.056 mg | 0.0175 mg | 0.028 mg |
Sorbitol | 50 mg | 80 mg | 25 mg | 40 mg |
Water for Injection USP | 1 mL | 1.6 mL | 0.5 mL | 0.8 mL |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.